Antisense Making Lots Of Sense To Biotech Researchers

Research Antisense Making Lots Of Sense To Biotech Researchers Author: Joshua Fischman, p. 14, 17. In the early 1980s, at an international conference on synthetic DNA and disease, molecular biologist James Hawkins first heard what chemists proposed to do with small pieces of synthetic genetic material called antisense DNA. And he was stunned. "It was the first time," he says, "that there was a clear concept: `Let's send these molecules into a cell and regulate a gene.' This was apocalyptic--tha

Written byJoshua Fischman
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Research

Antisense Making Lots Of Sense To Biotech Researchers

In the early 1980s, at an international conference on synthetic DNA and disease, molecular biologist James Hawkins first heard what chemists proposed to do with small pieces of synthetic genetic material called antisense DNA. And he was stunned.

"It was the first time," he says, "that there was a clear concept: `Let's send these molecules into a cell and regulate a gene.' This was apocalyptic--that's how profound it was for me." To some people, the concept, while profound, was also somewhat unbelievable. Indeed, Hawkins recalls, if you embraced it fully, "you were seen as a bit of a yahoo at the time, because the basic research wasn't established."

It's not unbelievable anymore. What the researchers were suggesting about antisense DNA at that international conference heralded what many experts now see as the next revolution in drug design. Hawkins is now president ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies